Long Acting Beta Agonist (laba) For Copd Therapeutics
1. Arcapta Neohaler patent expiration
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Dosage: POWDER
More Information on Dosage
ARCAPTA NEOHALER family patents
